Dr Abdullah Tarik Aslan is an internal medicine physician who graduated from Hacettepe University Faculty of Medicine as a high honour student in 2014 and completed his internal medicine training program at Hacettepe University Faculty of Medicine in 2019. He completed his obligatory duty as an internist in Burdur (a city located in southwest part of Turkey). During his career, he has worked with several important research groups. He performed a one-month observership activity at Hospital Universitario Virgen Macarena, Seville, Spain by endorsement of ESCMID (European Society of Clinical Microbiology and Infectious Diseases) in 2019. He also worked in Prof. Nordmann’s laboratory in Fribourg/Switzerland. Abdullah is still leading several projects with Prof. Murat Akova’s group in Turkey.
Abdullah is currently undertaking a PhD under the supervision of Professor David Paterson and Dr. Patrick N Harris. He is scholarly interested in clinical and molecular epidemiology of infections caused by antimicrobial resistant bacteria, pragmatic clinical trials, target trials, novel antimicrobials, synergistic interactions between antimicrobial agents, artificial intelligence and machine learning.
Abdullah has been awarded numerous awards and grants, such as the high honour student award of Hacettepe University, Pfizer Investigator Sponsored Research (Pre-clinical) grant, Pfizer Investigator Sponsored Research (Non-interventional Clinical) grants and an ECCMID Travel Grant. He has been invited to speak at national and international conferences, has published over 20 peer-reviewed manuscripts.
Publications
1. Zarakolu P, Aslan AT, Perry J. Evaluation of two commercial assays for the rapid confirmation of OXA-48 like carbapenemases produced by Klebsiella pneumoniae. Turk J Med Sci. 2018; 48: 679-686
2. Yeter HH, Yildirim T, Eyupoglu ND, Pasayev T, Aslan A, Cetik S, et al. Mild to moderate proteinuria is a heralding sign for acute kidney injury and mortality for intensive care unit patients. Turk J Med Sci. 2019; 49: 543-550.
3. Aslan AT, Akova M. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options. Expert Rev Anti Infect Ther. 2019; 17: 969-981.
4. Aslan AT, Akova M. Infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: clinical and molecular epidemiology and treatment strategies. Infect Dis Clin Microbiol. 2019; 3: 149-157. DOI: 10.36519/idcm.2019.19026
5. Aslan AT, Balaban HY. Hepatitis E virus: Epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol. 2020; 26: 5543-5560
6. Balaban HY, Aslan AT, Ayar SN, Dag O, Alp A, Simsek C, et al. Lack of awareness of Hepatitis B screening and vaccination in high-risk groups. Turk J Med Sci. 2021; 28: 1229-1233.
7. Aslan AT, Pashayev T, Dag O, Akova M. Comparison of Teicoplanin versus Vancomycin in Combination with Piperacillin- Tazobactam or Meropenem for the Risk of Acute Kidney Injury. Eur J Clin Microbiol Infect Dis. 2021; 40: 1953-1961.
8. Aslan AT, Halis S. Clinical Features and Pathophysiological Mechanisms of COVID-19- associated Gastrointestinal Manifestations. Euroasian J Hepatogastroenterol. 2021; 11: 81-86.
9. Aslan AT, Akova M. Current status of therapeutic alternatives for COVID-19: A narrative review. 2021; 3: 312-327.
10. Aslan AT, Balaban HY. An overview of SARS-COV-2-related hepatic injury. Hepatol Forum. 2021;2(3):122-127.
11. Aslan AT, Şaşmazer B, Ayar Y, Duran ZC, Akova M. Barriers Against Hepatitis B Vaccination in High-Risk Adults: A Cross-Sectional Study. Turk J Gastroenterol. 2022;33(5):427-433.
12. Aslan AT, Akova M. Piperacillin-Tazobactam Plus Vancomycin-Associated Acute Kidney Injury in Adults: Can Teicoplanin or Other Antipseudomonal Beta-Lactams Be Remedies? Healthcare (Basel). 2022;10(8):1582.
13. Isler B, Vatansever C, Özer B, Çınar G, Aslan AT, Stewart A, et al. Comparison of ceftazidime-avibactam susceptibility testing methods against OXA-48-like carrying Klebsiella blood stream isolates. Diagn Microbiol Infect Dis. 2022;104(1):115745.
14. Balaban HY, Aslan AT, Akdoğan-Kittana FN, Alp A, Dağ O, Ayar ŞN, et al. Hepatitis E Virus Prevalence and Associated Risk Factors in High-Risk Groups: A Cross-Sectional Study. Turk J Gastroenterol. 2022;33(7):615-624.
15. Tabah A, Elhadi M, Ballard E, Cortegiani A, Cecconi M, Unoki T, et al; COVISIT contributors. Variation in communication and family visiting policies in intensive care within and between countries during the Covid-19 pandemic: The COVISIT international survey. J Crit Care. 2022;71:154050.
16. Aslan AT, Akova M. The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations. Antibiotics 2022;11(2):277. DOI: 10.3390/antibiotics11020277
17. Isler B, Özer B, Çınar G, Aslan AT, Vatansever C, Falconer C, et al. Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: A multicentre prospective cohort study in an OXA-48 endemic setting. Eur J Clin Microbiol Infect Dis 2022;41(5):841–7
18. Aslan AT, Kırbaş E, Sancak B, Tanrıverdi ES, Otlu B, Gürsoy NC, et al. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting. Int J Antimicrob Agents. 2022;59(4):106554
19. Isler B, Aslan AT, Akova M, Harris P, Paterson DL. Treatment strategies for OXA-48- like and NDM producing Klebsiella pneumoniae infections. Expert Rev Anti-Infect Ther 2022;20(11):1389–00.
20. Aslan AT, Akova M, Paterson DL. Next-Generation Polymyxin Class of Antibiotics: A Ray of Hope Illuminating a Dark Road. Antibiotics (Basel). 2022;11(12):1711.
21. Buetti N, Tabah A, Loiodice A, Ruckly S, Aslan AT, Montrucchio G, et al. Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact II study. Critical Care. 2022;26:319.
22. Pascale R, Toschi A, Aslan AT, Massaro G, Maccaro A, Fabbricatore D, et al; CarDINe Study Group. This study is endorsed by ESGIAI, ESGBIES and SCARE Study Groups. Risk factors for Gram-negative bacterial infection of cardiovascular implantable electronic devices: multicenter observational study (CarDINe Study). Int J Antimicrob Agents. 2023:106734
23. Isler B, Falconer C, Vatansever C, Özer B, Çınar G, Aslan AT, et al. High prevalence of ArmA-16S rRNA methyltransferase among aminoglycoside-resistant Klebsiella pneumoniae bloodstream isolates. J Med Microbiol. 2022;71(12).
24. Tabah A, Buetti N, Staiquly Q, Ruckly S, Akova M, Aslan AT, et al. Epidemiology and outcomes of hospital-acquired bloodstreaminfections in intensivecare unit patients: theEUROBACT-2 internationalcohort study. Intensive Care Med 2023; 49(2): 178-190. DOI:10.1007/s00134-022-06944-2
25. Aslan AT, Tabah A, Köylü B, Kalem AK, Aksoy F, Erol C, et al. Epidemiology and risk factors of 28-day mortality of hospital-acquired bloodstream infection in Turkish intensive care units: a prospective observational cohort study. J Antimicrob Chemother 2023.